Distinguishing Extravascular from Intravascular Ferumoxytol Pools within the Brain: Proof of Concept in Patients with Treated Glioblastoma

References

1. 1.↵
   1. Ostrom QT,
   2. Gittleman H,
   3. Xu J, et al

   . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013. Neuro Oncol 2016;18:v1–75 doi:10.1093/neuonc/now207 pmid:28475809

   CrossRefPubMed
2. 2.↵
   1. Stupp R,
   2. Mason WP,
   3. van den Bent MJ, et al

   ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96 doi:10.1056/NEJMoa043330 pmid:15758009

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Stupp R,
   2. Hegi ME,
   3. Mason WP, et al

   ; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66 doi:10.1016/S1470-2045(09)70025-7 pmid:19269895

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Domingues P,
   2. Gonzalez-Tablas M,
   3. Otero A, et al

   . Tumor infiltrating immune cells in gliomas and meningiomas. Brain Behav Immun 2016;53:1–15 doi:10.1016/j.bbi.2015.07.019 pmid:26216710

   CrossRefPubMed
5. 5.↵
   1. Macdonald DR,
   2. Cascino TL,
   3. Schold SC Jr., et al

   . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–80 doi:10.1200/JCO.1990.8.7.1277 pmid:2358840

   Abstract
6. 6.↵
   1. Wen PY,
   2. Macdonald DR,
   3. Reardon DA, et al

   . Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol 2010;28:1963–72 doi:10.1200/JCO.2009.26.3541 pmid:20231676

   Abstract/FREE Full Text
7. 7.↵
   1. Okada H,
   2. Weller M,
   3. Huang R, et al

   . Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 2015;16:e534–42 doi:10.1016/S1470-2045(15)00088-1 pmid:26545842

   CrossRefPubMed
8. 8.↵
   1. Li H,
   2. Li J,
   3. Cheng G, et al

   . IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Clin Neurol Neurosurg 2016;151:31–36 doi:10.1016/j.clineuro.2016.10.004 pmid:27764705

   CrossRefPubMed
9. 9.
   1. Gunjur A,
   2. Lau E,
   3. Taouk Y, et al

   . Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis. J Med Imaging Radiat Oncol 2011;55:603–10 doi:10.1111/j.1754-9485.2011.02319.x pmid:22141608

   CrossRefPubMed
10. 10.↵
    1. Nasseri M,
    2. Gahramanov S,
    3. Netto JP, et al

    . Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question. Neuro Oncol 2014;16:1146–54 doi:10.1093/neuonc/not328 pmid:24523362

    CrossRefPubMed
11. 11.↵
    1. van Dijken BR,
    2. van Laar PJ,
    3. Holtman GA, et al

    . Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma; a systematic review and meta-analysis. Eur Radiol 2017;27:4129–44 doi:10.1007/s00330-017-4789-9 pmid:28332014

    CrossRefPubMed
12. 12.
    1. Grossman R,
    2. Shimony N,
    3. Hadelsberg U, et al

    . Impact of resecting radiation necrosis and pseudoprogression on survival of patients with glioblastoma. World Neurosurg 2016;89:37–41 doi:10.1016/j.wneu.2016.01.020 pmid:26805684

    CrossRefPubMed
13. 13.↵
    1. Melguizo-Gavilanes I,
    2. Bruner JM,
    3. Guha-Thakurta N, et al

    . Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? J Neurooncol 2015;123:141–50 doi:10.1007/s11060-015-1774-5 pmid:25894594

    CrossRefPubMed
14. 14.↵
    1. Nairz M,
    2. Theurl I,
    3. Swirski FK, et al

    . “Pumping iron”—how macrophages handle iron at the systemic, microenvironmental, and cellular levels. Pflugers Arch 2017;469:397–418 doi:10.1007/s00424-017-1944-8 pmid:28251312

    CrossRefPubMed
15. 15.↵
    1. McConnell HL,
    2. Schwartz DL,
    3. Richardson BE, et al

    . Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific. Nanomedicine 2016;12:1535–42 doi:10.1016/j.nano.2016.03.009 pmid:27071335

    CrossRefPubMed
16. 16.↵
    1. Toth GB,
    2. Varallyay CG,
    3. Horvath A, et al

    . Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int 2017;92:47–66 doi:10.1016/j.kint.2016.12.037 pmid:28434822

    CrossRefPubMed
17. 17.↵
    1. Varallyay CG,
    2. Nesbit E,
    3. Fu R, et al

    . High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle. J Cereb Blood Flow Metab 2013;33:780–86 doi:10.1038/jcbfm.2013.36 pmid:23486297

    CrossRefPubMed
18. 18.↵
    1. Iv M,
    2. Samghabadi P,
    3. Holdsworth S, et al

    . Quantification of macrophages in high-grade gliomas by using ferumoxytol-enhanced MRI: a pilot study. Radiology 2019;290:198–206 doi:10.1148/radiol.2018181204 pmid:30398435

    CrossRefPubMed
19. 19.↵
    1. Horvath A,
    2. Varallyay CG,
    3. Schwartz D, et al

    . Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas. Magn Reson Med 2018;80:224–30 doi:10.1002/mrm.27028 pmid:29205477

    CrossRefPubMed
20. 20.↵
    1. Bendszus M,
    2. Stoll G

    . Caught in the act: in vivo mapping of macrophage infiltration in nerve injury by magnetic resonance imaging. J Neurosci 2003;23:10892–96 pmid:14645484

    Abstract/FREE Full Text
21. 21.↵
    1. Jackson C,
    2. Ruzevick J,
    3. Phallen J, et al

    . Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol 2011;2011:732413 doi:10.1155/2011/732413 pmid:22190972

    CrossRefPubMed
22. 22.↵
    1. Wei B,
    2. Wang L,
    3. Zhao X, et al

    . The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression. Tumor Biol 2014;35:2923–29 doi:10.1007/s13277-013-1376-9 pmid:24375192

    CrossRefPubMed
23. 23.↵
    1. Heddleston JM,
    2. Li Z,
    3. McLendon RE, et al

    . The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009;8:3274–84 doi:10.4161/cc.8.20.9701 pmid:19770585

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Barajas RF Jr.,
    2. Chang JS,
    3. Segal MR, et al

    . Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MRI. Radiology 2009;253:486–96 doi:10.1148/radiol.2532090007 pmid:9789240

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Barajas RF Jr.,
    2. Hamilton BE,
    3. Schwartz D, et al

    . Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI defines glioblastoma pseudo-progression. Neuro Oncol 2019;21:517–26 doi:10.1093/neuonc/noy160 pmid:30277536

    CrossRefPubMed
26. 26.↵
    1. Barajas RF Jr.,
    2. Hodgson JG,
    3. Chang JS, et al

    . Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology 2010;254:564–76 doi:10.1148/radiol.09090663 pmid:20093527

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Ranjan S,
    2. Quezado M,
    3. Garren N, et al

    . Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases. BMC Cancer 2018;18:239 doi:10.1186/s12885-018-4131-1 pmid:29490632

    CrossRefPubMed
28. 28.↵
    1. Gordon SR,
    2. Maute RL,
    3. Dulken BW, et al

    . PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 2017;545:495–99 doi:10.1038/nature22396 pmid:28514441

    CrossRefPubMed
29. 29.↵
    1. Nguyen KL,
    2. Yoshida T,
    3. Kathuria-Prakash N, et al

    . Multicenter safety and practice for off-label diagnostic use of ferumoxytol in MRI. Radiology 2019;293:554–64 doi:10.1148/radiol.2019190477 pmid:31638489

    CrossRefPubMed